X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lonza will manufacture the ACU193 (sabirnetug) drug substance, the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease.
Lead Product(s): Sabirnetug
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2024
Details:
The proceends will be used to support development of a subcutaneous formulation of ACU193, a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: K2 HealthVentures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 13, 2023
Details:
The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Halozyme Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 06, 2023
Details:
Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 18, 2023
Details:
Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 17, 2023
Details:
ACU193 is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs whic is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
ACU193 is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble AβOs, which scientific evidence indicates are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hoag
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
